Novel Targets and Emerging Therapeutic Approaches track banner

A myriad of approaches and solutions are being investigated to create first-in-class biotherapeutics that take advantage of selective targeting of immune cell populations against a range of disease indications including oncology, rare diseases and autoimmune disorders. Join this leading faculty from around the world to comprehensively review the innovative ideas and latest clinical results for advancing the next generation of first-in-class medicines.

Thursday, 4 November

07:30 Registration and Morning Coffee



Chairperson's Remarks

Daniel S. Chen, MD, PhD

Boltbody Immune Stimulating Antibody Conjugates (ISACs): From Preclinical to Clinical Research

Edith A. Perez, MD, CMO, Bolt Biotherapeutics, Inc.

This talk will explore the biology of toll-like receptors in cancer, review preclinical studies and mechanism of action and activity of ISACs, and share an update from the global phase I/II first-in-human trial using BDC-1001 in patients advanced HER2-expressing solid tumors.

•    NEW DATA - This Presentation Contains New Data


Targeted Immune Cell Activation by Systemic Delivery of Toll-Like Receptor 9 Agonist Antibody Conjugates Induce Potent Anti-Tumor Immunity

Hong I. Wan, PhD, President, CEO and Co-Founder, Tallac Therapeutics, Inc.

Novel therapies engaging both innate and adaptive immune response may produce robust and durable anti-cancer immunity. Activation of toll-like receptor 9 (TLR9) by unmethylated CpG oligonucleotides (ODNs) promotes innate inflammatory responses and the induction of adaptive immunity. Several CpG-ODNs have demonstrated clinical response in melanoma patients by intra-tumoral injection. We developed a novel toll-like receptor agonist antibody conjugate (TRAAC) platform to deliver a potent TLR9 agonist (T-CpG) for targeted immune activation via systemic administration. TRAAC molecules demonstrated robust immune modulation and potent single agent anti-tumor activity in preclinical settings, suggesting therapeutic potential across multiple solid tumor malignancies. 

•    NEW DATA - This Presentation Contains New Data

10:00 Coffee Break in the Exhibit Hall with Poster Viewing

Antibody-Targeted Lipid-Nanoparticle Mediated Inhibition of the GPCR RXFP1 Signaling Pathway as a Therapeutic Approach for Ovarian Cancer

Itai Benhar, PhD, Professor, Biomedicine & Cancer Research, Tel Aviv University

The signaling pathway comprising the hormone Relaxin-H2 with its GPCR RXFP1 has been implicated in a number of malignancies. Here we describe a novel antibody-targeted, siRNA-carrying lipid nanoparticles, where the siRNA knocks down the expression of RXFP1. Upon delivery to human ovarian cancer cells, the treatment retards cell growth in vitro and in a xenograft mouse model.

•    NEW TALK - This Presentation Will be Given for the First Time

•    NEW DATA - This Presentation Contains New Data




Engineering Antibody Oligonucleotide Conjugates (AOCs): Taking Receptor-Mediated Uptake One Step Further

Arthur Levin, PhD, CSO, Avidity Biosciences

The promise of oligonucleotide therapeutics is to use Watson-Crick-Franklin base-pairing rules to design drugs rationally based on genomic information. That promise has remained elusive because of cell barriers to oligonucleotide uptake. Receptor-mediated uptake through bioconjugation oligonucleotides has changed that. Avidity’s AOC technology uses monoclonal antibodies to cell surface proteins that are internalized to facilitate the functional delivery of oligonucleotide therapeutics into a broad range of cell and tissue types.

Tracey Mullen, CEO, Abveris

Leveraging the natural immune repertoire for antibody discovery has distinct advantages for positive downstream outcomes, including efficacy, developability and safety; however, traditional antibody capture and screening methodologies typically fail to provide both the throughput and resolution required to thoroughly mine the full genetic diversity. The addition of the Berkeley Lights Beacon platform to the Abveris antibody discovery workflow has greatly enhanced the development process for therapeutic drug discovery, enabling the identification of functional, high affinity, species cross-reactive antibodies for rapid clinical advancement. 

12:15 Session Break
12:25 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
12:55 Session Break



Chairperson's Remarks

Ruud M. De Wildt, PhD, Director & Biopharm R&D Head, Lead Discovery, GlaxoSmithKline

The Role of Monoclonal Antibody Therapeutics in Tackling Global Health Challenges

Pauline Williams, CBE, MBBCh, FFPM, FMedSci, Senior Vice President and Head of Global Health R&D, GlaxoSmithKline

Monoclonal antibody therapies have historically been dismissed as viable global health interventions because of cost, supply chain and healthcare system limitations. The global response to the COVID-19 pandemic has demonstrated how disruptive approaches to R&D can transform therapeutic and preventative approaches in a short timescale. There is an increased awareness of the role mAbs can play in addressing public health challenges, including infectious diseases and anti-microbial resistance.

14:20 PLENARY:

Live Q&A

Panel Moderator:
Ruud M. De Wildt, PhD, Director & Biopharm R&D Head, Lead Discovery, GlaxoSmithKline
Pauline Williams, CBE, MBBCh, FFPM, FMedSci, Senior Vice President and Head of Global Health R&D, GlaxoSmithKline
14:30 Exhibit Hall & Last Chance Poster Viewing



Chairperson's Remarks

Hong I. Wan, PhD, President, CEO and Co-Founder, Tallac Therapeutics, Inc.

STK-012, an Alpha/Beta Selective IL-2 Mutein for the Activation of Antigen-Activated T Cells in Solid Tumors

Naiyer A. Rizvi, MD, CMO, Synthekine Inc.

High dose IL-2 induces complete responses in certain cancers. Its use is limited due to toxicities. To specifically stimulate antigen-activated CD25+ effector T cells and avoid systemic NK and naïve T cell activation, we have developed a pegylated, CD25/CD122-selective IL-2 mutein (STK-012). STK-012 avoids IL-2 mediated toxicity and may enable the specific expansion of antigen activated memory T cells in cancer patients leading to durable tumor response.


Engineering Cis-Targeted Immunomodulators to Enhance Their Selectivity and Effectiveness as Therapeutics

Yik Andy Yeung, PhD, CTO, Asher Biotherapeutics

Cytokines are potent immune modulators. However, systemic administration of cytokines for therapeutic purposes can result in pleotropic effects, with heterogenous activity across different cell types, ultimately limiting efficacy. We are pioneering a new approach with our cis-targeted cytokine therapies to activate only the immune cell types that drive desired responses. Our cis-targeted immunotherapies offer a new level of selectivity, with optimized efficacy and minimized toxicity.

•    NEW TALK - This Presentation Will be Given for the First Time

Amelie Kutschera, Single B Cell Scientist, Genovac Antibody Discovery

Traditional hybridoma and phage display methods have shown limited success in delivering therapeutic antibodies against difficult targets like most GPCRs and ion channels. Amelie Kutschera will present case studies of how Genovac has overcome this challenge by leveraging their core genetic immunization technology and Berkeley Lights’ Beacon OptoFluidic system to rapidly discover antibodies against challenging targets, focusing on GPCRs, from a variety of different animal species.  

16:50 Session Break

Multimeric IgM Antibodies Targeting DR5 are Potent and Rapid Inducers of Tumor Cell Apoptosis in Vitro and in Vivo

Angus M. Sinclair, PhD, Vice President, Immuno-oncology Research, IGM Biosciences

Death receptor 5 (DR5) naturally binds ligand TRAIL, inducing receptor trimerization and activation of apoptotic pathways in a broad range of cancers. Agonistic anti-DR5 IgG antibodies have been unsuccessful in clinical trials due to insufficient DR5 multimerization to induce apoptosis. We developed multivalent IgM antibody, IGM-8444, to efficiently cluster DR5 and induce potent cancer cell killing while maintaining a good preclinical safety profile. A Phase 1 clinical trial is currently ongoing.

  • NEW DATA - This Presentation Contains New Data​

Targeting Glycan-Mediated Immune Regulation in Cancer and Inflammatory Diseases

Li Peng, PhD, Senior Vice President, Research & Early Product Development, Palleon Pharmaceuticals

Glycan-mediated immune regulation plays an integral role in immune activation and tolerance and is often dysregulated in cancer and autoimmunity diseases. However, due to the promiscuity and redundancy of glycan-receptor interactions and glycans’ structural heterogeneity, therapeutic intervention of this axis is challenging with conventional therapeutic modalities. We developed a platform technology of enzymatic cell surface sialoglycan editing to enable drug development in glyco-immunology to treat cancer and inflammatory diseases.

  • NEW DATA - This Presentation Contains New Data​

Targeting the Immune Inhibitory Receptor LILRB4 to Treat Acute Myeloid Leukemia and Solid Tumors

Charlene Liao, PhD, President & CEO, Immune-Onc Therapeutics, Inc.

LILRB4, an immune inhibitory receptor expressed mostly on monocytes, has emerged as a compelling novel target for monocytic AML because LILRB4 signaling in leukemia cells mediates T cell suppression and tumor infiltration. IO-202 is an antagonist antibody to LILRB4, capable of activating T cells, inhibiting tumor growth, and blocking leukemia cell infiltration in preclinical studies. IO-202 is currently being evaluated in a phase 1 study in AML and CMML.

  • NEW DATA - This Presentation Contains New Data​
18:30 Close of Summit